Skin autofluorescence is high in patients with cirrhosis – Further arguing for the implication of Advanced Glycation End Products  by Maury, Elisa et al.
TLetters to the EditorSkin autoﬂuorescence is high in patients with cirrhosis – Further
arguing for the implication of Advanced Glycation End ProductsTo the Editor:
Guimaraes et al. recently reported that the Advanced Glyca-
tion End products (AGE) induces the production of reactive oxy-
gen species in hepatic stellate cells, providing an attractive
mechanism for the development of liver ﬁbrosis in the metabolic
syndrome [1]. As mentioned by the authors, the deleterious con-
sequences of the accumulation of AGEs are well documented in
the context of diabetes [2] or chronic renal failure [3], whereas
they have been less reported in cirrhotic patients. High levels of
Ne-(carboxymethyl)lysine ‘‘CML’’ [4] or other ﬂuorescent AGEs
[5] have been detected in the serum of these patients using ELISA
or liquid chromatography–mass spectrometry assays [6], but
these analytical methods are not routinely available, and the
accumulation in other tissues, requiring biopsies, has not been
reported. The optic properties of most AGEs may in fact help to
provide further evidence for this accumulation.
The ﬂuorescence of AGEs, as used by Guimaraes et al. to con-
ﬁrm the glycation of AGE-BSA that they applied to hepatic cells
[1], allows for assessment of the accumulation of AGEs in the
skin, in a simple and non-invasive manner, by measuring skin
autoﬂuorescence (AF) with the AGE-Reader (DiagnOptics BV,
Groningen, The Netherlands). Brieﬂy, the AGE-Reader illuminates
approximately 1 cm2 of skin (which is guarded against surround-
ing light) with an excitation light source of 300–420 nm (peak
excitation 350 nm). AF is calculated by dividing the average
light intensity emitted per nm over the 420- to 600-nm range
by the average light intensity emitted per nm over the 300- to
420-nm range. The value of this technique is supported by corre-
lations between skin autoﬂuorescence and collagen-linked ﬂuo-
rescence (CLF; excitation at 370 nm, emission at 440 nm)
following pepsin digestion, and the pentosidine (by HPLC), Ne-
(carboxyethyl)lysine (CEL) and Ne-(carboxymethyl)lysine (CML)
(by gas chromatography and mass spectrometry) concentrations
in skin biopsies, (r = 0.47–0.62, p <0.002) [7], and it is a strong
predictor of cardiac mortality in patients with type 2 diabetes
[8]. We are not aware of any report about skin AF in patients with
cirrhosis. The potential inﬂuence of an icterus, that may modify
the optic properties of the skin, is also unknown.able 1. AutoFluorescence results in patients with cirrhosis, type 2 diabetes and
n
Age
Glycemia (mg/dl)
Bilirubinemia (mmol/L)
AF
Control 
subjects
7
48 ± 6
-
-
1.9 ± 0.2
Cirrhosis with 
icterus
13
56 ± 10
114 ± 13
159  ± 138
2.2 ± 0.6
Journal of HepatologyUsing the AGE-Reader, we have measured the forearm skin AF
of 32 patients with cirrhosis (diagnosis on liver biopsy; alcoholic,
viral, and metabolic origins), 16 patients with type 2 diabetes and
at least one previous cardiovascular event, and seven healthy
control subjects who were members of our staff (physicians,
nurses). All participants signed an informed consent. Among
the cirrhotic patients, 13 had jaundice icterus which was con-
ﬁrmed by the dosage of bilirubinemia. The results are presented
as mean ± SD, compared by ANOVA with a Bonferroni correction.
As expected, the 16 patients with diabetes had higher skin AF
results than control subjects (3.4 ± 0.7; p <0.001), but the skin AF
were also higher in the patients with cirrhosis as compared with
the control subjects (2.4 ± 0.6 vs 1.9 ± 0.2; p <0.05). As shown in
Table 1, the icteric patients had lower results than those without
icterus (p = 0.08 vs cirrhosis without icterus). We, therefore, mea-
sured the AF of six normal subjects before and after painting their
forearm with bilirubin (Calbiochem, La Jolla, CA 92037): this
immediately reduced the AF (before: 1.7 ± 0.2, after painting with
bilirubin: 1.4 ± 0.2; p <0.05).
Although these results are preliminary, the higher AF, as we
found, further argues for the implication of AGEs in liver ﬁbrosis.
Of course, such clinical data do not replace mechanistic studies:
as mentioned by Guimaraes et al., the liver is critical for the clear-
ance of AGEs [9], so their accumulation in the tissues of patients
with cirrhosis may in fact be a consequence, rather than a cause,
of liver damage. Even in this case, deleterious effects of this accu-
mulation may occur outside the liver: further vascular complica-
tions have been reported in patients with type 2 diabetes and
Non alcoholic Fatty Liver Disease (NAFLD) [10]. In any case, we feel
that thehepatologists should be informed that the accumulation of
AGEs in tissues canbe evaluatedbynon-invasive techniques, aswe
did, and that cirrhosis and icterus inﬂuence the results.
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Cirrhosis without 
icterus
19
56 ± 10
109 ± 40
27  ± 9
2.7 ± 0.7
T2D
16
59 ± 8
190 ± 62
-
3.4 ± 0.7
p
n.s.
<0.001
<0.001 
<0.001 
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To the Editor:
Similar to previous recommendations [1–3], a stage-dependent
therapeutic strategy of non-malignant and non-cirrhotic portal
vein thrombosis (PVT) is advocated in the recent Baveno V con-
sensus [4]. At recent or acute stage of PVT, the predominant goals
of treatment are to maximize the rate of portal vein recanaliza-
tion and to prevent thrombus extension upstream into the supe-
rior mesenteric vein and its possible secondary intestinal
infarction. At the old or chronic stage, the primary therapeutic
objectives are shifted to the prevention and treatment of variceal
bleeding and management of portal biliopathy. Despite the fact
that this uniform therapeutic strategy is widely approved, no
clear deﬁnition for staging of PVT has been postulated until
now. Thus, the heterogeneity of the criteria might greatly pre-
clude the standardization of the above-mentioned therapeutic
strategy and the further evaluation of the outcomes.
It has been widely accepted that the formation of portal caver-
noma has been considered the ‘‘tipping point’’ between acute and
chronic PVT. Once portal cavernoma is detected, the patients are
regarded as having entered the chronic stage. However, this does
not completely fall in line with our clinical practice. Fig. 1 dem-
onstrates the transverse computed tomography (CT) images
obtained at the hilum in one patient who was admitted to our
department due to a recent onset of abdominal pain in the
absence of complications of portal hypertension. Contrast-
enhanced CT scans showed cavernous vessels around the throm-
bosed portion of the main portal vein (Fig. 1, A). This ﬁnding
suggests that PVT might have been at the chronic phase accord-
ing to the prior criteria. Conversely, non-enhanced CT scans
showed a high intraluminal density within the portal vein
(Fig. 1, panel B), which was strongly suggestive of a fresh throm-
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bus because the protein fraction of hemoglobin in the clot
resulted in the elevated CT attenuation value. From our perspec-
tive, despite the detection of portal cavernoma, this group of
patients should be classiﬁed into the acute stage and treated with
anticoagulation and thrombolysis to resolve abdominal symp-
toms and recanalize the thrombosed portal vein.
Both experimental and clinical observations have indicated
that the cavernous transformation could rapidly develop within
a few days after the formation of fresh PVT [5,6]. Despite the
fact that the compensatory mechanism of collateral circulation
is very helpful to drain intestinal congested blood and maintain
total hepatic blood ﬂow [7], thrombus progression and exten-
sion still go on, which may result in progressive abdominal
presentations in some patients with PVT. Accordingly, we pos-
tulated that the therapeutic strategy of the early period of cav-
ernous transformation might be similar to that of the acute
stage.
In the end, based on our previous observations [8,9], we
attempted to draw an elementary schematic diagram demon-
strating the possible course of portal vein thrombosis and the
progression of symptoms (Fig. 2). But it should be noted that
the natural history of EHPVO is a complex and dynamic process,
and thus this new framework needs to be further improved in
many aspects, such as clariﬁcation of the role of thrombotic
recurrence and the prognostic signiﬁcance of ascites.
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